Core Viewpoint - Xenon Pharmaceuticals reported significant progress in its clinical trials for azetukalner, a novel KV7 potassium channel opener, with upcoming milestones including topline data for Phase 3 studies in epilepsy and neuropsychiatry [2][3]. Business Highlights and Anticipated Milestones - Azetukalner is in late-stage clinical development for multiple indications, including focal onset seizures (FOS), primary generalized tonic-clonic seizures (PGTCS), major depressive disorder (MDD), and bipolar depression (BPD) [3][14]. - The Phase 3 X-TOLE2 study for azetukalner in FOS is expected to report topline data in the first half of March 2026, with an NDA submission anticipated in the second half of the year [5][6]. - Five additional Phase 3 studies of azetukalner are ongoing, with topline data from the X-NOVA2 study for MDD expected in the first half of 2027 [5][6]. - The company has raised pro forma cash of $716 million, extending its cash runway into the second half of 2027 [5][9]. Financial Results - For the fourth quarter of 2025, Xenon reported a net loss of $105.3 million, compared to a net loss of $65.7 million in the same period of 2024 [12][20]. - Research and development expenses increased to $87.7 million for Q4 2025, up from $59.5 million in Q4 2024, primarily due to ongoing clinical studies for azetukalner [12][20]. - General and administrative expenses rose to $22.1 million for Q4 2025, compared to $18.0 million in Q4 2024, driven by increased personnel-related costs [12][20].

Xenon Pharmaceuticals FY Conference Summary Company Overview - **Company**: Xenon Pharmaceuticals (NasdaqGM:XENE) - **Event**: 44th Annual J.P. Morgan Healthcare Conference - **Date**: January 12, 2026 - **Key Presenters**: Ian Mortimer (President and CEO), Chris Kenny (Chief Medical Officer), Darren Kline (Chief Commercial Officer), Tucker Kelly (CFO) [1][2] Core Focus Areas Lead Molecule: Azetukalner - **Indications**: Developed for epilepsy and neuropsychiatry - **Clinical Development**: Most advanced potassium channel modulator in late-stage clinical development with over 800 patient years of efficacy and safety data [3][4] - **Dosing**: Once-daily dosing with no titration required, which is a significant advantage over other CNS drugs [5] Epilepsy Market Insights - **Prevalence**: Epilepsy is the fourth most common neurological condition, with a lifetime risk of 1 in 26 [6] - **Patient Population**: Approximately 3 million Americans have epilepsy, with focal onset seizures representing about 60% of the market [6][7] - **Unmet Need**: About half of epilepsy patients are not receiving adequate treatment, indicating a significant market opportunity for azetukalner [7][8] Clinical Trial Updates - **Phase IIb Trial (X-TOLE)**: Randomized 325 subjects, showing a 52.8% reduction in seizures at the highest dose (25 mg) with significant statistical significance (P < 0.05) [9][10] - **Open-Label Extension**: Patients showed over 90% reduction in seizure burden over 48 months, with nearly 40% achieving 12 months of seizure freedom [13][15] - **Phase III Trials**: Two parallel trials (X-TOLE2 and X-TOLE3) for focal onset seizures, with the first readout expected in March 2026 [19][20] Neuropsychiatry Development - **Major Depressive Disorder (MDD)**: A smaller phase II study showed a clear dose response with rapid onset of efficacy, leading to ongoing phase III trials [22][27] - **Bipolar Depression**: New study (EXCED) initiated to address this significant unmet need [27] Early-Stage Pipeline - **Nav1.7 Program**: Focused on a novel analgesic targeting pain pathways, currently in phase I clinical trials [28][29] - **Genetic Insights**: The program leverages genetic findings related to the SCN9A gene, which is linked to pain perception [29][30] Strategic Objectives - **Integration**: Aim to become a fully integrated biopharma company, focusing on discovering, developing, and commercializing proprietary molecules [36][38] - **Market Positioning**: Emphasis on building a strong commercial team with deep epilepsy experience to ensure successful product launch [55][56] Key Takeaways - **Market Opportunity**: Significant unmet medical needs in both epilepsy and neuropsychiatry present a strong market opportunity for azetukalner [8][27] - **Clinical Confidence**: Robust clinical data supports the efficacy and safety of azetukalner, positioning it as a potential first-line treatment in its categories [18][19] - **Future Outlook**: Successful outcomes in ongoing trials could lead to a substantial expansion of Xenon's portfolio and market presence in the coming years [59][62]

Core Insights - Xenon Pharmaceuticals Inc. is advancing its Phase 3 portfolio, particularly focusing on azetukalner for epilepsy and neuropsychiatry, with significant milestones expected in the near future [1][2] Phase 3 Azetukalner Program in Epilepsy & Depression - The topline data for the X-TOLE2 Phase 3 study of azetukalner in focal onset seizures (FOS) is anticipated in March 2026, followed by a New Drug Application (NDA) submission in the second half of 2026 [4] - Five additional Phase 3 studies of azetukalner are ongoing, targeting various indications in epilepsy and neuropsychiatry, with topline data from the X-NOVA2 study in major depressive disorder (MDD) expected in the first half of 2027 [4][5] - The X-TOLE2 study has completed enrollment with 380 patients, and the data collected will support the upcoming topline readout [5] Broader Pipeline Opportunity - Azetukalner is a novel KV7 potassium channel opener, currently in late-stage clinical trials for epilepsy, MDD, and bipolar depression (BPD), representing a significant advancement in treatment options [7][10] - The company is also developing early-stage candidates targeting NaV1.7 and KV7 for pain management, with preliminary Phase 1 data expected in 2026 to support Phase 2 studies [11][12] About Epilepsy and Focal Onset Seizures - Epilepsy affects approximately 3 million adults in the U.S., with focal onset seizures being a common form that presents a substantial unmet medical need due to the inadequacy of existing treatments for many patients [9]